Thu, Apr 17, 2014, 3:27 PM EDT - U.S. Markets close in 33 mins.

Recent

% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • scistats scistats Sep 14, 2013 1:23 AM Flag

    Heads up guys.

    Monday, September 9, 2013 10:25 a.m. ET
    Zalicus Inc at Rodman & Renshaw Global Investment Conference
    Millennium Broadway Hotel, New York, NY US

    Minute 10, Second 18 (10:18)
    “The safety database. When I showed this slide three-four months ago [June 5, 2013; Jefferies 2013 Healthcare Conference] , there were 200 patients that had been exposed to Z160. We now have over 450 patients that have been exposed to our moiety.”

    “LSR started enrollment 3 months ahead of PHN.” Jason Napodano (Seeking Alpha, Aug 1 01:46 PM).

    Combined, the LSR and PHN trials recently completed enrollment of 140 patients each, for a total of 280 (ClinicalTrials.gov).

    When Dr. Corrigan mentioned 200 patients (above), he was including previous trials involving Z160 (Phase I) and NMED 160.

    However, BASED ON WHAT HE SAID on Sept. 9th, we do know for certain that from June 5th to September 9th, Zalicus added safety data on 250 additional patients for the LSR and PHN trials.

    This is 96 days during which 2.6 patients were enrolled each day (both trials combined), so each trial, on average enrolled 1.3 patients per day during this period.

    If Zalicus initiated LSR Phase 2a on September 4, 2012, the number of days to August 1, 2013 would be 331 days. But, let’s reduce the average of 1.3 by a factor of three to be conservative. This would be 0.433 patients enrolled per day, on average. 0.433 * 331 = 143 patients enrolled by August 1, 2013. Now, add in even more “buffer”, let’s say enrollment actually completed on August 15, 2013.

    So, from August 15th, we add 6 weeks for the last patients to complete the trial. With 99% confidence, Zalicus will complete enrollment of their LSR study, with final top line data in the box on or before September 25th, 2013, which gives Zalicus plenty of time to analyze the data for the primary endpoint for release on or before October 7th, averting a R/S. If the LSR is good, I expect to hear on or before Oct. 7th. Merck's old high dose NMED160 data says it is.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • As much as i dislike you for what you did to zalicus stock in the past i believe you are correct and thanks for posting that!

      Sentiment: Strong Buy

    • Keep trying. Your wild guesses are nothing more than that. Data isn't coming before October 7, you P.O.S. liar. You're as bad as the idiot bashers. Maybe even worse because at least they are obvious in what they are doing.

    • hey thanks for this. ill be buying more next week. i think anything below .70 is honestly a steal. if the news is positive, zlcs will likely never be at this price range again. gotta play to win.

    • If you don't know what the info below means, do some homework because you will be even more confident in Z160.

      Jan. 28 /PRNewswire/ -- Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

      In the study, leconotide, when given intravenously to treat neuropathic pain, was selective for calcium channels involved with pain and it did not act on other calcium channels to cause side effects, as has been seen in studies of other calcium channel blockers used for treating pain. It was efficacious alone, but more so when it was given in combination with a potassium channel opener (flupirtine). The study also showed that leconotide, unlike currently available treatments of this type, does not have to be administered directly into the spinal fluid to achieve pain relief, and so could have the potential to be delivered via nasal spray, transdermal patch, or pill.

      Sentiment: Strong Buy

 
ZLCS
1.22-0.1300(-9.63%)3:26 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.